BRPI0414568A - combinações de drogas para o tratamento de neoplasmas - Google Patents

combinações de drogas para o tratamento de neoplasmas

Info

Publication number
BRPI0414568A
BRPI0414568A BRPI0414568-2A BRPI0414568A BRPI0414568A BR PI0414568 A BRPI0414568 A BR PI0414568A BR PI0414568 A BRPI0414568 A BR PI0414568A BR PI0414568 A BRPI0414568 A BR PI0414568A
Authority
BR
Brazil
Prior art keywords
neoplasms
treatment
drug combinations
patient
chlorpromazine
Prior art date
Application number
BRPI0414568-2A
Other languages
English (en)
Inventor
Margaret S Lee
M James Nichols
Yanzhen Zhang
Curtis Keith
Original Assignee
Combinatorx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Combinatorx Inc filed Critical Combinatorx Inc
Publication of BRPI0414568A publication Critical patent/BRPI0414568A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMBINAçõES DE DROGAS PARA O TRATAMENTO DE NEOPLASMAS". A presente invenção representa um método para tratar um paciente tendo um câncer ou outro neoplasma administrando-se ao paciente clorpromazina ou um análogo de clorpromazina e um agente antiproliferativo simultaneamente ou dentro de 14 dias um do outro em quantidades suficientes para tratar o paciente.
BRPI0414568-2A 2003-09-18 2004-09-16 combinações de drogas para o tratamento de neoplasmas BRPI0414568A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50431003P 2003-09-18 2003-09-18
PCT/US2004/030368 WO2005027842A2 (en) 2003-09-18 2004-09-16 Combinations of drugs for the treatment of neoplasms

Publications (1)

Publication Number Publication Date
BRPI0414568A true BRPI0414568A (pt) 2006-11-07

Family

ID=34375474

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414568-2A BRPI0414568A (pt) 2003-09-18 2004-09-16 combinações de drogas para o tratamento de neoplasmas

Country Status (16)

Country Link
US (1) US20050137185A1 (pt)
EP (1) EP1670477A2 (pt)
JP (1) JP2007505914A (pt)
KR (1) KR20070012618A (pt)
CN (1) CN1878556A (pt)
AR (1) AR046163A1 (pt)
AU (1) AU2004273910A1 (pt)
BR (1) BRPI0414568A (pt)
CA (1) CA2538570A1 (pt)
IL (1) IL174232A0 (pt)
IS (1) IS8398A (pt)
MX (1) MXPA06003066A (pt)
NO (1) NO20061325L (pt)
RU (1) RU2006112834A (pt)
TW (1) TW200518752A (pt)
WO (1) WO2005027842A2 (pt)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569853B1 (en) * 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
US20050100508A1 (en) * 2003-11-12 2005-05-12 Nichols M. J. Methods for identifying drug combinations for the treatment of proliferative diseases
US20050158320A1 (en) * 2003-11-12 2005-07-21 Nichols M. J. Combinations for the treatment of proliferative diseases
US20050154455A1 (en) * 2003-12-18 2005-07-14 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis
EP1802641B8 (en) 2004-10-08 2012-03-07 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
US8012949B2 (en) 2004-10-08 2011-09-06 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS
TW200716141A (en) * 2005-05-05 2007-05-01 Combinatorx Inc Compositions and methods for treatment for neoplasms
US8076371B2 (en) * 2006-03-09 2011-12-13 Bernstein Lawrence R Gallium compositions for the treatment of liver cancer and methods of use
JP2009530414A (ja) 2006-03-17 2009-08-27 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ イリノイ ビスホスホネート化合物及び方法
US20090117203A1 (en) * 2006-03-23 2009-05-07 Tmrc Co., Ltd. Kit for cancer treatment and pharmaceutical composition for cancer treatment
CA2649877A1 (en) 2006-04-24 2007-12-21 Gloucester Pharmaceuticals Gemcitabine combination therapy
WO2007146730A2 (en) 2006-06-08 2007-12-21 Gloucester Pharmaceuticals Deacetylase inhibitor therapy
US9539241B2 (en) 2006-07-12 2017-01-10 Mobius Therapeutics, Llc Apparatus and method for reconstituting a pharmaceutical and preparing the reconstituted pharmaceutical for transient application
US9205075B2 (en) 2006-07-12 2015-12-08 Mobius Therapeutics, Llc Apparatus and method for reconstituting a pharmaceutical and preparing the reconstituted pharmaceutical for transient application
US7806265B2 (en) * 2006-07-12 2010-10-05 Mobius Therapeutics, Llc Apparatus and method for reconstituting a pharmaceutical and preparing the reconstituted pharmaceutical for transient application
WO2008066807A1 (en) * 2006-11-28 2008-06-05 Ziopharm Oncology, Inc. Use of indolyl-3-glyoxylic acid derivatives including indibulin, alone or in combination with further agents for treating cancer
JP2010514801A (ja) 2006-12-29 2010-05-06 グラスター ファーマシューティカルズ， インコーポレイテッド ロミデプシンの精製
US20120082659A1 (en) * 2007-10-02 2012-04-05 Hartmut Land Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations
US8212010B2 (en) * 2008-02-25 2012-07-03 Expression Drug Designs, Llc Sphingosine 1-phosphate antagonism
JP5537000B2 (ja) 2008-08-13 2014-07-02 富士通株式会社 マルチメディア放送・同報サービス通信制御方法及び装置
WO2010086964A1 (ja) * 2009-01-28 2010-08-05 株式会社 静岡カフェイン工業所 がん治療のための併用療法
JP6257324B2 (ja) 2010-06-04 2018-01-10 アブラクシス バイオサイエンス， エルエルシー 膵臓がんの処置方法
CA2804795A1 (en) 2010-07-12 2012-01-19 Nicholas Vrolijk Romidepsin solid forms and uses thereof
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
WO2012079075A1 (en) 2010-12-10 2012-06-14 Concert Pharmaceuticals, Inc. Deuterated phthalimide derivatives
CA2860862A1 (en) * 2011-01-11 2012-07-19 Mount Sinai School Of Medicine Methods and compositions for treating cancer and related methods
US9134297B2 (en) 2011-01-11 2015-09-15 Icahn School Of Medicine At Mount Sinai Method and compositions for treating cancer and related methods
US9314473B2 (en) 2011-02-03 2016-04-19 Pop Test Oncology Limited Liability Company System and method for diagnosis and treatment
JP2014509323A (ja) * 2011-02-28 2014-04-17 マックマスター ユニヴァーシティ ドーパミン受容体遮断薬による癌の処置
CN102274238B (zh) * 2011-06-30 2012-10-03 山东弘立医学动物实验研究有限公司 一种治疗胰腺癌的药物组合物
EP2758403B1 (en) 2011-09-21 2016-04-27 Inception Orion, Inc. Tricyclic compounds useful as neurogenic and neuroprotective agents
CN104114175A (zh) * 2011-10-28 2014-10-22 黄奇英 用于清除癌干细胞的医药组合物
WO2013130849A1 (en) 2012-02-29 2013-09-06 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
US8809299B2 (en) * 2012-03-28 2014-08-19 Mcmaster University Combination therapy for the treatment of cancer
WO2013159026A1 (en) 2012-04-20 2013-10-24 Concert Pharmaceuticals, Inc. Deuterated rigosertib
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
EP2922838B1 (en) 2012-10-22 2018-03-14 Concert Pharmaceuticals Inc. Solid forms of {s-3-(4-amino-1-oxo-isoindolin-2-yl)(piperidine-3,4,4,5,5-d5)-2,6-dione} .
JP6348115B2 (ja) 2012-10-26 2018-06-27 ザ ユニバーシティー オブ クイーンズランド がん療法のためのエンドサイトーシス阻害剤および抗体の使用
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
WO2014110322A2 (en) 2013-01-11 2014-07-17 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
WO2015080681A1 (en) * 2013-11-29 2015-06-04 Andac Ahmet Cenk Phenothiazine-pyrimidine-2,4(1 h, 3h)-dione compounds for the treatment of cancer
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
US20160120876A1 (en) * 2014-04-28 2016-05-05 Chi-Ying Huang Pharmaceutical composition for treatment of cancer using phenothiazine
WO2016016268A1 (de) 2014-07-28 2016-02-04 Technische Universität Dresden Thymin- und chinazolin-dion-derivate zur hemmung von hsp27
WO2016062265A1 (zh) * 2014-10-24 2016-04-28 朗齐生物医学股份有限公司 莫诺苯宗药物在用于制备治疗癌症的医药组合物中的用途
WO2017000084A1 (zh) * 2015-06-30 2017-01-05 上海交通大学 Promethazine在制备抗肝癌和/或结肠癌和/或肺癌产品中的应用
WO2017180086A1 (en) * 2016-04-11 2017-10-19 Pop Test Oncology Limited Liability Company System and method for diagnosis and treatment
JOP20170053B1 (ar) 2016-03-02 2021-08-17 Eisai Randd Man Co Ltd مترافقات جسم مضاد وعقار أساسها إيريبولين وطرق استخدامها
CA3058492A1 (en) * 2016-04-06 2017-10-12 Noxopharm Limited Radiotherapy improvements
JP2019513828A (ja) 2016-04-06 2019-05-30 ノクソファーム リミティド 改善された薬物動態を有するイソフラボノイド組成物
KR102005887B1 (ko) * 2016-12-09 2019-07-31 서울대학교산학협력단 뇌종양의 예방 또는 치료용 약학 조성물
AU2021247415A1 (en) 2020-03-30 2022-09-29 Noxopharm Limited Methods for the treatment of inflammation associated with infection

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2645640A (en) * 1953-07-14 Phenthiazine derivatives
US5104858A (en) * 1988-09-29 1992-04-14 Yale University Sensitizing multidrug resistant cells to antitumor agents
US6569853B1 (en) * 2000-11-06 2003-05-27 Combinatorx, Incorporated Combinations of chlorpromazine and pentamidine for the treatment of neoplastic disorders
US6642221B1 (en) * 2000-11-15 2003-11-04 Parker Hughes Institute Vanadium compounds as anti-proliferative agents
WO2002057244A1 (en) * 2001-01-19 2002-07-25 Cytokinetics, Inc. Phenothiazine kinesin inhibitors
AU2003256511A1 (en) * 2002-07-11 2004-02-02 Combinatorx, Incorporated Combinations of drugs for the treatment of neoplasms
US20050054708A1 (en) * 2003-07-28 2005-03-10 Nichols Matthew James Combinations of drugs for the treatment of neoplasms
US20050080075A1 (en) * 2003-08-25 2005-04-14 Nichols M. James Formulations, conjugates, and combinations of drugs for the treatment of neoplasms

Also Published As

Publication number Publication date
TW200518752A (en) 2005-06-16
WO2005027842A8 (en) 2006-05-18
KR20070012618A (ko) 2007-01-26
IS8398A (is) 2006-04-05
WO2005027842A2 (en) 2005-03-31
CN1878556A (zh) 2006-12-13
US20050137185A1 (en) 2005-06-23
IL174232A0 (en) 2006-08-01
MXPA06003066A (es) 2006-06-20
EP1670477A2 (en) 2006-06-21
NO20061325L (no) 2006-06-06
AR046163A1 (es) 2005-11-30
WO2005027842A3 (en) 2005-12-22
CA2538570A1 (en) 2005-03-31
JP2007505914A (ja) 2007-03-15
AU2004273910A1 (en) 2005-03-31
RU2006112834A (ru) 2007-10-27

Similar Documents

Publication Publication Date Title
BRPI0414568A (pt) combinações de drogas para o tratamento de neoplasmas
ATE307608T1 (de) Kombination von doctaxel und rhumab her2 zür krebsbehandlung
BR0115166A (pt) Combinações de drogas (por exemplo, cloropromazina e pentamidina) para o tratamento de distúrbios neoplásticos
CY1119109T1 (el) Συσκευη που μπορει να εμφυτευθει που περιεχει υλικο μητρας που μπορει να απορροφηθει και ραπαμυκινη για την προληψη ή την θεραπεια αγγειο-πολλαπλασιαστικων ασθενειων
DE69521994D1 (de) Zusammensetzungen welche dna zerstoerende agentien und p53 enthalten
WO2004006906A3 (en) Methods for the treatment of neoplasms
BR0213100A (pt) Combinações para o tratamento de distúrbios imuniinflamatórios
BR0109446A (pt) Medicamento para a aplicação intracorpórea, uso de um xanteno halogenado, composição farmacêutica, e, método de tratamento
DE60222137D1 (de) Zuckerderivate von hydromorphon, dihydromorphin und dihydroisomorphin, zusammensetzungen davon und verwendung zur vorbeugung und behandlung von schmerzen
DE69933208D1 (de) Verwendung von zusammensetzungen mit antiseptika und/oder die wundheilung fördernden wirkstoffen für den tieferen atemwegstrakt
DE60308256D1 (de) Beschichtetes medizinsches Implantat zur Behandlung von Gefässerkrankungen
ATE307625T1 (de) Wirkstoffabgabesysteme zur behandlung von gefässerkrankungen
ES2123642T3 (es) Metodo para el tratamiento del cancer por terapia conjunta con derivados de 2'-halometilideno y un agente antineoplasico especifico de fase s o fase m.
WO2005011572A3 (en) Combination of drugs for the treatment of neoplasms
DE602004016376D1 (de) Kombination von et-743 mit 5-fluorouracil pro-drugs zur behandlung von krebs
ATE141045T1 (de) Schlankmachende zusammensetzung
DE60018409D1 (de) Verwendung von antiseptika zur herstelllung von arzneimitteln zur prophylaxe und behandlung von infektionen und/ oder funktionellen gewebeumformungen im körperinneren
ATE357912T1 (de) Intrakorporelle medikamente zur hoch- energetischen phototherapeutischen behandlung von krankheiten
DE60043886D1 (de) Formulierungen mit povidon-iod zur behandlung von wunden
ATE185274T1 (de) Therapeutisches mittel gegen drohenden abortus
DE60216292D1 (de) Calciumtrifluoracetat mit zytotoxischer wirkung
BR0311180A (pt) Métodos para o tratamento de doenças e condições respiratórias utilizando um inibidor seletivo da inos
BR9914570A (pt) Processo para o tratamento da esquizofrenia bem como agentes para o emprego neste processo
BR0317772A (pt) Método de tratamento de um distúrbio de comportamento, uso de um composto, e, agente terapêutico para um distúrbio de comportamento
KR930702016A (ko) 골다공증 치료제

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.